Form 4 Filing for CRISPR Therapeutics AG

On October 6, 2026, James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, reported a series of transactions. Kasinger acquired 1,990 common shares via the exercise of a stock option at a price of $0.00 per share, increasing his post-transaction shares to 96,774. Subsequently, he disposed of 1,990 common shares at a weighted average price of $60.0408, with prices ranging from $60.00 to $60.08. This resulted in 94,784 shares remaining in his possession. These transactions were executed under a Rule 10b5-1 trading plan. The exercised stock option was originally granted on May 31, 2017, with 25% vesting on May 31, 2018, and the remainder vesting monthly over the subsequent 36 months. The option had an exercise price of $13.62 per share.